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Abstract
Tau and Aβ assemblies of Alzheimer’s disease (AD) can be visualized in living subjects using positron emission tomography 
(PET). Tau assemblies comprise paired helical and straight filaments (PHFs and SFs). APN-1607 (PM-PBB3) is a recently 
described PET ligand for AD and other tau proteinopathies. Since it is not known where in the tau folds PET ligands bind, 
we used electron cryo-microscopy (cryo-EM) to determine the binding sites of APN-1607 in the Alzheimer fold. We iden-
tified two major sites in the β-helix of PHFs and SFs and a third major site in the C-shaped cavity of SFs. In addition, we 
report that tau filaments from posterior cortical atrophy (PCA) and primary age-related tauopathy (PART) are identical to 
those from AD. In support, fluorescence labelling showed binding of APN-1607 to intraneuronal inclusions in AD, PART 
and PCA. Knowledge of the binding modes of APN-1607 to tau filaments may lead to the development of new ligands with 
increased specificity and binding activity. We show that cryo-EM can be used to identify the binding sites of small molecules 
in amyloid filaments.
Keywords Positron emission tomography · Alzheimer’s disease · Posterior cortical atrophy · Primary age-related 
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Introduction
Assembly of a small number of soluble proteins into insolu-
ble amyloid filaments underlies the majority of age-related 
neurodegenerative diseases [20]. Tau is the most commonly 
affected of these proteins. It assembles into filaments in a 
number of diseases, including Alzheimer’s disease (AD), 
chronic traumatic encephalopathy (CTE), progressive supra-
nuclear palsy (PSP), globular glial tauopathy (GGT), corti-
cobasal degeneration (CBD) and Pick’s disease (PiD). Six 
tau isoforms are expressed in the adult human brain. Three 
isoforms have three microtubule-binding repeats, whereas 
the other three have four repeats each. All six tau isoforms 
assemble in AD and CTE, but only four-repeat tau forms 
inclusions in PSP, GGT and CBD; PiD is a three-repeat tau 
proteinopathy.
AD is defined by the presence of abundant intraneuronal 
tau inclusions and extracellular Aβ deposits [41]. Cogni-
tive impairment and neurodegeneration correlate better with 
the number and distribution of tau inclusions than with Aβ 
assemblies. Although silver staining, amyloid dyes and anti-
bodies that label tau assemblies in post mortem brains have 
been available for many years, PET ligands that detect tau 
inclusions in living subjects have only recently been devel-
oped. Cross-sectional studies have shown that lower brain 
volumes are more strongly associated with tau-PET than 
Aβ-PET signals [8]. A prospective longitudinal study has 
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indicated that the levels of tau-PET signal predict rates of 
brain atrophy [29], in agreement with neuropathological 
studies [4].
First-generation tau PET probes can be divided into three 
major chemical groups, with 18F-THK5351 [22], 18F-flor-
taucipir [7] and 11C-PBB3 (pyridinyl-butandienyl-benzothi-
azole 3) [35] being representative compounds. 11C-PBB3 is 
the most promising for visualizing inclusions made of only 
3R or 4R tau isoforms. However, rapid conversion into a 
metabolite results in low entry of unmetabolized 11C-PBB3 
into the brain. Recently, it has been shown that second-gen-
eration tau PET probe 18F-APN-1607, also called 18F-PM-
PBB3 (propanol modification of PBB3), a compound with 
high metabolic stability, labels brain regions with abundant 
tau inclusions in AD and PSP [26, 46]. Here we used cryo-
EM structure determination to identify the binding sites of 
APN-1607 in PHFs and SFs from AD.
Materials and methods
Clinical history and neuropathology
Tau filaments were extracted from the frontal cortex of 
neuropathologically confirmed cases of AD with sarkosyl 
(case 2 in reference [15]) or by affinity chromatography 
[28]. Occipital cortex from a previously described indi-
vidual (case 18 in reference [15]) with PCA was used for 
tau filament extraction with sarkosyl. Tau filaments were 
extracted with sarkosyl from the entorhinal cortex or hip-
pocampus of 3 previously undescribed individuals with 
PART. Case 1, with definite PART, was a male who died 
aged 88 following a 2-year history of progressive memory 
loss. In addition to tau changes, prominent large- and small-
vessel cerebrovascular disease associated with white mat-
ter loss was observed; small, healed cerebral infarcts were 
present in the frontal cortex and basal ganglia. There was 
substantial atrophy of the visual system, consistent with a 
history of long-term blindness. This individual, who suf-
fered numerous head injuries, was declared legally blind 
at age 21. Signs of a healed subdural haemorrhage were 
seen at autopsy. α-Synuclein and TDP-43 inclusions were 
not observed. Case 2, with definite PART, was a male who 
died aged 65 with cognitive impairment. There were signs 
of extensive small vessel disease; TDP-43 inclusions were 
present in nerve cells and glial cells, mostly in some sub-
cortical regions. α-Synuclein inclusions were not detected. 
Case 3, with possible PART, was a female who died aged 
88 following a 2-year history of progressive memory loss. 
α-Synuclein or TDP-43 inclusions were not observed. Addi-
tional findings are summarized in Table 1.
Histology, immunohistochemistry and silver 
staining
Histology and immunohistochemistry were carried out as 
described [45]. Briefly, 8 μm paraffin-embedded tissue sec-
tions were treated for antigen retrieval, prior to overnight 
incubation with primary antibodies at room temperature. 
The sections were counterstained with haematoxylin/eosin 
and Luxol fast blue. Primary antibodies were: RD3 tau [10], 
anti-4R tau [12], AT8 [36], anti-phospho TDP-43 [23, 27], 
anti-Aβ 6F/3D [33] and anti-Aβ 4G8 [32] (Supplemental 
Fig. 1, online resource). Secondary antibodies were either 
ImmPRESS HRP anti-rabbit or anti-mouse IgG (Vector, 
Burlingame, CA), with 3,3′-diaminobenzidine used as 
Table 1  Cases of Alzheimer’s 
disease, posterior cortical 
atrophy and primary age-related 
tauopathy used for sarkosyl 
extraction and cryo-EM
Alzheimer’s disease (AD) (case 2) and posterior cortical atrophy (PCA) (case 18) have been described 
[15]. Primary age-related tauopathy (PART) cases 1–3 have not been described before. There were 
no known disease-causing mutations in MAPT. PART cases 1–3 had a heterozygous T185S change in 
TMEM106B (gene encoding transmembrane protein 106B). PART case 1 had a heterozygous R62H 
change in TREM2 (gene encoding triggering receptor expressed on myeloid cells 2) and a heterozygous 
N357S change in TIA1 (gene encoding cytotoxic granule-associated RNA-binding protein). Whole-exome 
sequencing did not detect mutations known to cause AD, Parkinson’s disease, frontotemporal dementias 
or amyotrophic lateral sclerosis. PART case 1 was also heterozygous for mutations C195F and D1005V 
in CRB1 (gene encoding crumbs homologue 1). Biallelic mutations in CRB1 cause retinal disease [31], 
consistent with the development of blindness in this individual. His mother also suffered from retinal dis-
ease and was blind. Braak tau stages, Thal Aβ phases and Olichney Aβ angiopathy scales were determined 
according to references [4, 39, 47]
Diagnosis Gender Age at 
death (y)






AD F 82 Frontal cortex VI 5 3 ε4/ε4
PCA M 63 Occipital cortex VI 5 3 ε4/ε4
PART1 M 88 Hippocampus IV 0 0 ε2/ε3
PART2 M 65 Entorhinal cortex I 0 0 ε3/ε3
PART3 F 88 Hippocampus III 2 3 ε3/ε4
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chromogen. Some sections were silver-impregnated using 
the method of Gallyas-Braak [5].
Fluorescence staining of tau deposits 
with APN‑1607
Fluorescence staining of brain sections from cases of AD, 
PCA and PART with APN-1607 were done as described 
[40, 46]. Briefly, deparaffinized 6 μm sections were incu-
bated in 50% ethanol containing 25 μM APN-1607 at room 
temperature for 30 min. They were rinsed in 50% ethanol 
for 5 min., washed twice in water for 3 min. and mounted 
in non-fluorescent media (Vectashield, Vector Laborato-
ries). Fluorescence images were captured using a DM4000 
microscope (Leica) equipped with a custom filter cube, as 
described [46].
Whole‑exome sequencing
Target enrichment made use of the SureSelectTX human 
all-exon library (V6, 58 megabase pairs; Agilent) and high-
throughput sequencing was carried out using a HiSeq 4000 
(sx75 base-pair paired-end configuration; Illumina). Bioin-
formatics analyses were performed as described [17].
Extraction of tau filaments
Sarkosyl-insoluble material was extracted from hippocam-
pus and cortex (frontal, occipital and entorhinal) [19]. 
Tissues were homogenized in 10 ml/g tissue of extraction 
buffer consisting of 10 mM Tris–HCl, pH 7.5, 10% sucrose, 
0.8 M NaCl, 5 mM EDTA, 1 mM EGTA and a protease 
and phosphatase inhibitor (Thermo Fisher). Homogenates 
were spun at 20,000 g for 20 min. and supernatants retained. 
Pellets were homogenized in 5 ml/g extraction buffer and 
centrifuged at 20,000g for 20 min. Both supernatants were 
combined, brought to 1% sarkosyl and incubated for 60 min. 
at room temperature. Following a 60 min. centrifugation at 
100,000g, pellets were resuspended in 250 μl/g extraction 
buffer and spun at 20,000g for 20 min. The resulting super-
natants were centrifuged at 100,000 g for 1 h. For cryo-
EM, pellets were resuspended in 25 μl/g tissue of 20 mM 
Tris–HCl, pH 7.5, 100  mM NaCl. Tau filaments were 
immunopurified from the frontal cortex of two individuals 
with neuropathologically confirmed AD (cases a and b), as 
described [28].
Binding of APN‑1607 to PHFs and SFs.
APN-1607 was synthesised as described [26]. A 10 mM 
solution was prepared using anhydrous dimethyl sulfox-
ide (DMSO, Thermo Fisher) and stored at − 20 °C. Tau 
filaments were sarkosyl-extracted from frontal cortex of 
an individual who had died with a neuropathologically 
confirmed diagnosis of AD (case 2 in reference [15]) and 
incubated with 100 μM APN-1607 in 20 mM Tris–HCl, pH 
7.5, 100 mM NaCl, 1% DMSO, for 3 h at room tempera-
ture (25 μl/g tissue). The concentration of APN-1607 was 
2.5 nmol/g tissue. Controls were incubated with buffer con-
taining 1% DMSO. Given the photosensitivity of APN-1607, 
these experiments were carried out in the dark, except for a 
yellow light source with a wavelength greater than 525 nm.
Electron cryo‑microscopy
Following a 1 min spin at 3000 g, 3 μl of supernatant were 
placed on glow-discharged holey carbon grids (Quantifoil 
Au R1.2/1.3, 300 mesh) and plunge-frozen in liquid ethane 
using an FEI Vitrobot Mark IV. The images of PART case 2 
were acquired using a Falcon III detector in linear mode on 
a Glacios cryo-transmission electron microscope (Thermo 
Fisher) at 200 kV. All other images were acquired using 
a Gatan K2 summit detector in counting mode on a Titan 
Krios (Thermo Fisher) at 300 kV. A GIF quantum energy 
filter (Gatan) was used with a slit width of 20 eV to remove 
inelastically scattered electrons. Further details are given in 
Supplemental Fig.  2, online resource.
Helical reconstruction
Movie frames were motion-corrected and dose-weighted 
using the motion correction implementation of RELION 
[51]. Aligned and non-dose weighted micrographs were 
used to estimate the contrast transfer function (CTF) by 
CTFFIND-4.1 [42]. Other image-processing steps were 
performed using helical reconstruction in RELION [24, 
43]. Filaments were picked manually and extracted using 
an inter-box distance of 14.1 Å. For reference-free 2D classi-
fication, segments with a box size comprising an entire heli-
cal crossover were downscaled by a factor of 2–4 to speed 
up calculations. Different types of filament were separated 
by reference-free 2D classifications and segments contribut-
ing to suboptimal 2D averages discarded. For immunopu-
rified AD tau filaments, as well as sarkosyl-extracted tau 
filaments from PART cases 1 and 3, initial 3D models were 
constructed de novo from 2D class averages comprising an 
entire helical crossover using the relion_helix_inimodel2d 
program [43]. For the other datasets, EMD-0259 (PHF) and 
EMD-0260 (SF) (from AD case 2 in reference [15]) were 
used as the initial 3D models. Helical twists were estimated 
either by crossover distances from 2D class averages, or 
according to those reported [15]. Segments for 3D auto-
refinement were then re-extracted using a box size compris-
ing approximately 33% of the helical crossover, without 
downscaling. With an initial 3D model that was low-pass 
filtered to 10 Å, 3D auto-refinement was carried out for 
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several rounds with optimization of helical twist and rise, 
after reconstructions had shown separation of β-strands 
along the helical axis. Since PHF protofilaments are related 
by an approximate  21 screw symmetry [18], additional heli-
cal symmetry was applied from the initial 3D refinements. 
We then performed Bayesian polishing and CTF refine-
ment, followed by 3D classification without further image 
alignment, to remove segments that yielded suboptimal 3D 
reconstructions. To further improve the structure of the 
β-helix region of SF protofilament 2 from PART case 3, we 
used focused 3D classification (with signal subtraction) of 
V337-S356 without further image alignment. Final recon-
structions were sharpened using standard post-processing 
procedures in RELION [51]. Overall resolution estimates 
were calculated from the Fourier shell correlations (FCSs) 
at 0.143 between two independently refined half-maps, using 
phase-randomisation to correct for convolution effects of a 
generous, soft-edged solvent mask that extended to 20% of 
the height of the box. Using the relion_helix_toolbox pro-
gram [43], helical symmetries were imposed on the post-
processed maps, which were then used for model building 
and refinement. For further details, see Supplemental Figs. 2 
and 3, online resource.
Model building and refinement
6HRE for PHFs [15], 6HRF for SFs [15] and 6NWP for CTE 
type I filaments [16] were used as initial references. Models 
containing five β-sheet rungs were refined in real-space by 
PHENIX [1] using local symmetry to keep all rungs identi-
cal. For SFs from PART case 3, the models were refined 
against the map before focused 3D classification, followed 
by real-space refinement in COOT [13] of only the turns 
between β-strands 4 and 5 against the map after focused 3D 
classification. MolProbity [6] was used for model validation. 
To confirm the absence of overfitting, FSC curves between 
one half-map and the model, which was refined against the 
other half-map, were checked. Additional details are given 
in Supplemental Figs. 2 and 3, online resource.
Quantitation of extra densities
For each dataset, 3 independent refinements were carried 
out by dividing the cryo-EM images 3 times into different 
half-sets in RELION. They used the same references and 
parameters, without optimisation of helical symmetry. Each 
reconstruction was post-processed, with a low-pass filter of 
3.0 Å and a B-factor of − 70 Å2 for the PHF maps, and a 
low-pass filter of 3.55 Å and a B-factor of − 55 Å for the 
SF maps. Helical symmetry was applied to post-processed 
half-maps using the relion_helix_toolbox program [43]. The 
reconstructions with a box size of 256 pixels and a pixel size 
of 1.15 Å were up-sampled to 558 pixels, from which the 
central rung could be extracted in an integer number of pix-
els (i.e., 9 pixels) along the helical axis. The central 18 slices 
were used for analysis. Binary masks were then created for 
the different binding sites; a solvent region extending 29 
pixels around the entire filaments; and for residues 349–370 
(binding sites 1, 2a, 2b, 3, 4) or 318–340 (binding sites 5, 
6a, 6b) of tau. Relative densities were calculated as follows:
where: Max(binding site) is the highest pixel value within 
the mask for the binding site; Avg(solvent) is the average 
pixel value in the solvent region; Max(protein) is the highest 
pixel value in the protein density for residues 349–370 and 
318–340 of tau (using the numbering of the 441 amino acid 
isoform of human brain tau).
Results and discussion
Structures of tau filaments from Alzheimer’s disease 
with APN‑1607
We added APN-1607 to sarkosyl-insoluble tau filaments 
from the frontal cortex of case 2 of AD (in reference [15]), 
prior to imaging by cryo-EM (+APN-1607). We used the 
PET ligand at 2.5 nmol/g. The Bmax of 18F-PM-PBB3 for 
tau aggregates in AD frontal cortex has been reported to 
be 5.7 nmol/g [46]. The mean concentration of sarkosyl-
insoluble tau is around 1 nmol/g cerebral cortex from AD 
[49]. The approximate molar APN-1607: tau ratio was there-
fore 2.5. As controls, we imaged tau filaments following the 
addition of only buffer (-APN-1607). By using helical recon-
struction in RELION [24, 43], we determined the structures 
of PHFs to 3.0 Å (+APN-1607) and 2.8 Å (–APN-1607). 
There were fewer SFs, giving resolutions of 3.6 Å (+APN-
1607) and 3.2 Å (–APN-1607). These maps enabled us to 
study additional densities that were well separated from 
those of tau (Fig. 1; Supplemental Fig. 3, online resource).
For PHFs, we observed additional densities in the + APN-
1607 map compared to the –APN-1607 map (Fig. 1a, c, e), 
with the overall structure being unchanged (Fig. 2a). The 
root mean-square deviation between refined atomic coordi-
nates in both maps was 0.4 Å. In the -APN-1607 map, densi-
ties in these grooves were weaker, approaching the intensity 
levels of noise features in the solvent region, suggesting that 
the extra densities in the +APN-1607 map corresponded to 
the PET ligand. In a difference map, these sites showed up 
as well-resolved peaks when displayed at a threshold of 11 
standard deviations (Fig. 1c).
One additional density was present in the groove between 
the side chains of R349 and Q351 from β6 of the Alzheimer 
Relative density (binding site) =
[
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tau fold (binding site 1). Two additional densities were 
observed in the groove between the side chains of Q351 
and K353 (binding sites 2a and 2b), possibly reflecting the 
width of this groove (Figs. 1, 2b). It is possible that side-to-
side interactions between APN-1607 molecules at sites 2a 
and 2b, e.g. π-stacking between the π-electron-conjugated 
backbone of APN-1607, are required for binding at site 2b, 
and that APN-1607 may not be able to bind to site 2b when 
site 2a is empty. Despite a similar hydrophobic environment, 
the density at site 1 was weaker than at site 2a. These same 
grooves between the side chains that formed binding sites 
1, 2a and 2b were previously identified by molecular dock-
ing among the predicted binding sites for multiple tau PET 
ligands [21, 38].
In SFs, protofilament 1 was better defined than protofila-
ment 2. Nevertheless, we observed similar extra densities in 
both protofilaments at binding sites 1, 2a and 2b, as well as 
an additional elongated density within the C-shaped cavity 
(binding site 3) (Fig. 1b, d, e). When comparing the + APN-
1607 and –APN-1607 maps, we observed a 7° difference 
in the orientation of β7 for protofilament 1 and a 3° differ-
ence for protofilament 2 (Fig. 2c, d). This suggests that the 
binding of APN-1607 induces a conformational change that 
enlarges the size of the C-shaped cavity in SFs. Even in 
the absence of APN-1607, this cavity is wider in SFs than 
in PHFs. Thus, an approximate 12° difference in the turn 
between β6 and β7 was observed when comparing PHFs and 
SFs in the –APN-1607 maps (Fig. 2e). When displaying the 
difference maps for SFs at a threshold of 8 standard devia-
tions, all the binding sites showed up as well-resolved peaks 
and the conformational changes resulting from APN-1607 
binding led to additional differences in SFs (Fig. 1d).
To rule out that the weak densities at sites 1, 2a and 
2b were caused by random noise, we performed 3 map 
refinements for each dataset, by dividing the cryo-EM 
images 3 times into different half-sets. We then quantified 
the densities at binding sites 1, 2a and 2b in each of the 6 
half-set reconstructions relative to the densities of tau (see 
Methods). The additional densities at the various binding 
sites were weaker than the densities of tau. For PHFs, the 
additional densities were approximately 40% relative to 
the density of tau for site 1, 60% for site 2a and 40% for 
site 2b. For SFs, the relative densities were approximately 
55%, 50% and 45%, respectively. In the absence of APN-
1607, they were 5–15% in PHFs and SFs (Fig. 3a).
Fig. 1  Cryo-EM maps of PHFs and SFs from Alzheimer’s disease 
with APN-1607. a, b Cryo-EM maps of tau filaments without (-APN-
1607) and with (+APN-1607) PET ligand. c, d, Overlay of positive 
(orange) and negative (purple) difference maps and -APN1607 maps 
(grey). SF protofilaments 1 and 2 are labelled as PF-1 and PF-2. 
Amino acids R349, Q351 and K353 are indicated, with the C-shaped 
cavities outlined by stippled lines. The thresholds in the difference 
maps were 11 standard deviations for PHFs and 8 standard deviations 
for SFs. e, Alzheimer tau protofilament core with APN-1607 binding 
sites. Major binding sites 1, 2a, 2b and 3 are shown in orange; minor 
binding sites 4, 5, 6a and 6b are indicated in yellow
▸
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To exclude that sarkosyl binds to the same sites and inter-
feres with APN-1607 binding, we determined the cryo-EM 
structures of tau filaments immunopurified from the frontal 
cortex of two neuropathologically confirmed cases of AD 
(cases a and b) (Supplemental Fig.4, online resource). For 
case (a), cryo-EM micrographs showed PHFs and SFs in a 
ratio of approximately 4:1. Using helical reconstruction in 
RELION [24, 43], we determined the structures of PHFs to 
2.9 Å and SFs to 7.0 Å resolution (Supplemental Figs. 3b 
and 4a, online resource). For case (b), we observed mainly 
PHFs and determined their structure to 3.2 Å resolution 
(Supplemental Figs. 3b and 4b, online resource). We found 
no significant differences between sarkosyl-extracted and 
immunopurified filaments (Supplemental Fig. 4c, online 
resource). Immunopurified filaments also showed weak 
densities in both grooves. Therefore, we exclude sarkosyl as 
the reason for weak additional densities in the –APN-1607 
structures. It is possible that molecules from the brain bind 
with low occupancy at these sites.
APN-1607 (Fig. 3b) fits into the elongated densities 
observed at binding sites 1, 2a and 2b, suggesting that it 
binds parallel to the long helical axis of amyloid filaments 
(Fig. 3c, d). A similar mode of binding has been reported 
for thioflavin-T, Congo red and luminescent conjugated oli-
gothiophenes [25, 34, 44]. It remains to be seen if other tau 
PET ligands bind in the same grooves of the Alzheimer tau 
fold. Binding sites 1 and 2 have Q351 in common, which 
adopts an extended conformation. Although the orienta-
tion of its amide headgroup cannot be determined at the 
current resolution, it probably forms a hydrogen-bonded 
ladder along the filament axis, providing a rigid partition 
between sites 1 and 2. The positively charged headgroups 
of R349 and K353 are kept at a distance from Q351 by elec-
trostatic interactions with the carboxylic groups of D348 
and D358, creating predominantly hydrophobic grooves with 
polar edges as the binding sites. It follows that bound APN-
1607 with a hydrophobicity log p value of 4.01 is stabilized 
mostly by hydrophobic interactions; occasional hydrogen 
bonds may form between its polar atoms and the side chains 
and/or carbonyl oxygens of tau. Additional densities are 
mostly featureless along the filament axis, suggesting that 
they do not obey helical symmetry. Therefore, the relative 
positions of individual APN-1607 molecules in the direction 
parallel to the helical axis cannot be determined from the 
Fig. 2  Alzheimer tau folds with and without APN-1607. a, Overlay 
of the structures of PHFs (+APN-1607; -APN-1607; PDB: 6HRE). b 
Overlay of R349-Q351 (binding site 1) and Q351-K353 (binding site 
2) of PHFs. Flanking residues are shown as main-chain traces. c, d, 
Overlay of the structures of SF protofilaments 1 (c) and 2 (d) (+APN-
1607; -APN-1607; PDB: 6HRF). e, Overlay of SF protofilaments 1 
and 2, and the PHF protofilament (−APN-1607). The structures were 
aligned based on residues 363–380 of tau (in the numbering of the 
441 amino acid isoform of human brain tau)
703Acta Neuropathologica (2021) 141:697–708 
1 3
cryo-EM maps. In addition, the blurring that results from the 
helical averaging in the reconstruction process complicates 
the interpretation of the relative densities in terms of the 
stoichiometry of ligand binding at the different sites.
The elongated shape of the additional density at binding 
site 3, with a density level of approximately 70% relative to 
that of tau (Fig. 3a, d), suggests that in SFs APN-1607 is 
able to bind in a direction nearly perpendicular to the helical 
axis, although the exact orientation and relative positions of 
individual molecules cannot be determined from the cryo-
EM map. This site was not identified by molecular docking 
[21, 38]. At binding site 3, APN-1607 is probably stabilized 
on one side by hydrophobic interactions with APN-1607 
molecules at binding sites 1 and 2b. On the other side, APN-
1607 faces two additional densities of unknown nature. They 
have also been observed in the cryo-EM maps of PHFs and 
SFs from the frontal cortex of 4 cases of AD [15]. The find-
ing that in PHFs there is less space between these additional 
densities and the β-helix at the tip of the C may explain 
why binding site 3 is not occupied. Weaker densities were 
also found in grooves other than those of binding sites 1 
and 2. We refer to these minor binding sites as 4, 5, 6a and 
6b (Fig. 1e; Supplemental Fig. 5 , online resource). In SFs, 
binding at sites 5, 6a and 6b was only seen in protofilament 
2. Binding at site 6b was not observed in PHFs. A statistical 
analysis of the relative densities of all APN-1607 binding 
Fig. 3  Binding of APN-1607 
to PHFs and SFs. a, Relative 
densities at binding sites 1, 2a, 
2b and 3 in cryo-EM maps of 
PHFs and SFs. Means, standard 
deviations and individual values 
of 6 half-set reconstructions 
are shown. Unpaired two-
tailed t-test: ****p < 0.0001. b, 
Chemical structure of APN-
1607 (PM-PBB3). c, d, Top 
views and side views of the 
extra densities in the APN-1607 
binding sites of PHF (c) and SF 
(d) maps. The models of APN-
1607 are shown near these extra 
densities at the same scale
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sites in PHFs and SFs from AD is given in Supplemen-
tal Fig. 6, online resource. The presence of an additional 
major APN-1607 binding site in SFs suggests that the ratio 
between PHFs and SFs could influence ligand binding, in 
particular the Bmax.
The tau protofilament folds of CTE, PiD and CBD differ 
from that of AD [14, 16, 18, 50]. Binding studies have sug-
gested that APN-1607 may also be able to image tau inclu-
sions of PiD and CBD [46]. It will be important to identify 
the binding sites of APN-1607 in tau filaments from these 
diseases. In the Pick fold, molecular docking has identified 
a potential binding site for APN-1607 in the groove between 
R349 and Q351 of tau [37, 46].
Structures of tau filaments from posterior cortical 
atrophy and primary age‑related tauopathy
PCA, a variant of AD, is characterized by an initial decline 
in visual processing, with the early presence of abundant 
tau inclusions and Aβ assemblies in the occipital cortex [3]. 
PART [9] has been described as a pathological continuum, 
ranging from localized entorhinal and hippocampal tau 
inclusions in individuals with normal or mildly impaired 
cognition to widespread tau inclusions in patients with tan-
gle-only dementia (TD) [2, 9, 48]. It has also been proposed 
that PART is part of the events that lead to the presence of 
abundant plaques and tangles in neocortex, with a clinical 
picture of AD [11].
We determined cryo-EM structures of tau filaments 
from the occipital cortex of PCA (Fig. 4a). PHFs and SFs 
were present in a ratio of 9:1. Reconstructions calculated in 
RELION [24, 43] were identical to those determined pre-
viously from the frontal cortex of AD [15, 18]. The reso-
lutions were 3.6 Å for PHFs and 5.2 Å for SFs (Fig. 4a; 
Supplemental Fig. 3b, online resource). We also imaged 
two cases of definite PART and one case of possible PART 
by cryo-EM and immunohistochemistry (Fig. 4b; Supple-
mental Figs. 7–10, online resource). Silver-positive tangles 
were present in the hippocampus of cases 1 and 3 and the 
entorhinal cortex of case 2. Sarkosyl-insoluble tau filaments 
from the hippocampus of PART case 1, who suffered from 
long-term blindness, had 26% PHFs and 61% SFs; 13% were 
Fig. 4  Cryo-EM maps of tau filaments from posterior cortical atrophy 
and primary age-related tauopathy. a PHF and SF from the occipital 
cortex of a case of PCA. b PHFs and SFs from the hippocampus of 
PART cases 1 and 3 and PHF from the entorhinal cortex of PART 
case 2; 13% of filaments from PART case 1 were CTE type I tau fila-
ments
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CTE type I filaments [16]. The presence of CTE type I fila-
ments was consistent with a history of head trauma and the 
presence of tau inclusions around blood vessels in occipital 
lobe (Supplemental Fig. 7, online resource). PART case 2 
had only PHFs, whereas PART case 3 had 42% PHFs and 
58% SFs. TDP-43 inclusions were present in subcortical 
brain regions of PART case 2 (Supplemental Fig. 8, online 
resource). Aβ deposits were observed in cortical regions 
of PART case 3, but not PART case 1 or 2 (Supplemental 
Fig. 10, online resource). We determined the structures of 
PHFs to resolutions of: 3.2 Å (PART case 1), 5.8 Å (PART 
case 2) and 2.8 Å (PART case 3). For SFs, the resolutions 
were: 2.8 Å (PART case 1) and 2.7 Å (PART case 3).
In previous maps [15, 18], the density of SF protofilament 
2 was not of sufficient quality to allow unambiguous chain 
tracing in the direction along the helical axis, in particu-
lar the β-helix region. Given the overall appearance of the 
density in the plane perpendicular to the helical axis, where 
the interactions between amino acid side chains shaped the 
Alzheimer tau fold, we assumed that the main chain would 
adopt the same fold in both protofilaments. At 2.7 Å, the 
cryo-EM map from PART case 3 has the highest known 
resolution for a SF (Figs. 4b and 5). We carried out further 
3D classification that showed two distinct conformations 
(Fig. 5a). They were distinguished by flips of the peptide 
bonds between E342 and its flanking residues, S341 and 
K343 in conformation 2, which led the turn between strands 
4 and 5 of the β-helix to connect to strands in adjacent rungs, 
with the rest of the structure being unchanged (Fig. 5b). 
Conformation 1 was identical to the tau fold of the PHF and 
SF protofilament 1. Conformation 2 was more similar to the 
CTE tau fold. The mixing of conformations suggests that in 
a substantial proportion of SFs, protofilament 2 can give rise 
to a subtype of the Alzheimer tau fold that is distinct from 
the fold of the PHF and from that of the SF protofilament 
1. This could play a role in the asymmetric packing of SF 
protofilaments.
Fig. 5  Two conformations of Alzheimer tau fold in SF protofilament 
2 from PART case 3. a Overlay of two conformations of the Alzhei-
mer tau fold from SF protofilament 2. The structures were aligned 
based on amino acids 304–340 of tau (in the numbering of the 441 
amino acid isoform of human brain tau). b Close-up view showing 
that the difference between conformations was a flip of the peptide 
groups between E342 and its flanking residues, S341 and K343
Fig. 6  Staining of tau inclusions with fluorescent APN-1607. Sec-
tions from the frontal cortex of AD, occipital cortex of PCA, hip-
pocampus of PART cases 1 and 3, and entorhinal cortex of PART 
case 2 were stained with APN-1607. The same cases of the disease 
were used as for cryo-EM. a AD; b PCA; c PART case 1; d PART 
case 2; e PART case 3. Scale bar, 50 μm
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These findings establish that the Alzheimer tau fold can 
form in the absence of Aβ deposits and support the observa-
tion that homogenates from the brains of patients with AD 
and PART had similar seeding activities [30].
Staining of tau inclusions from Alzheimer’s disease, 
posterior cortical atrophy and primary age‑related 
tauopathy with APN‑1607
Since APN-1607 is fluorescent, its reactivity with tau inclu-
sions can be investigated in brain sections [46]. APN-1607 
labelled numerous nerve cell body inclusions in tissue sec-
tions from the cases of AD (Fig. 6a), PCA (Fig. 6b) and 
PART (Fig. 6c–e) used for cryo-EM, providing a link, not 
only with AD, but also with PCA and PART. Some neuritic 
plaques were also labelled (Fig. 6a). Triple staining of brain 
sections with APN-1607, an antibody against phosphoryl-
ated tau and Gallyas-Braak silver staining has shown binding 
of APN-1607 to tau inclusions in AD [46]. In PART, the 
number of stained inclusions was proportional to the Braak 
stages. Thus, PART case 2, with tau pathology at Braak 
stage I, had the smallest number of fluorescent inclusions 
(Fig. 6d). It follows that APN-1607 may also be useful as a 
PET ligand for the tau inclusions of PCA and PART.
Conclusion
Taken together, our findings show that APN-1607 binds in 
the β-helix region of PHFs and SFs. This work establishes 
the use of cryo-EM to study the binding of small molecule 
compounds to amyloid filaments, which will allow the 
design of new PET ligands with increased specificity and 
binding activity for a range of neurodegenerative diseases.
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